168 related articles for article (PubMed ID: 32503882)
21. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac.
Chan TS; Yu H; Moore A; Khetani SR; Tweedie D
Drug Metab Dispos; 2013 Dec; 41(12):2024-32. PubMed ID: 23959596
[TBL] [Abstract][Full Text] [Related]
22. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
23. Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.
Carls A; Jedamzik J; Witt L; Hohmann N; Burhenne J; Mikus G
Br J Clin Pharmacol; 2014 Dec; 78(6):1433-40. PubMed ID: 25139487
[TBL] [Abstract][Full Text] [Related]
24. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
25. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4.
Li AP; Doshi U
Drug Metab Lett; 2011 Aug; 5(3):183-91. PubMed ID: 21722087
[TBL] [Abstract][Full Text] [Related]
26. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.
Reinach B; de Sousa G; Dostert P; Ings R; Gugenheim J; Rahmani R
Chem Biol Interact; 1999 Jun; 121(1):37-48. PubMed ID: 10418969
[TBL] [Abstract][Full Text] [Related]
28. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
[TBL] [Abstract][Full Text] [Related]
29. Indinavir Increases Midazolam
Tian DD; Leonowens C; Cox EJ; González-Pérez V; Frederick KS; Scarlett YV; Fisher MB; Paine MF
Drug Metab Dispos; 2019 Jul; 47(7):724-731. PubMed ID: 31028057
[TBL] [Abstract][Full Text] [Related]
30. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
32. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
Wiebe ST; Meid AD; Mikus G
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):527-542. PubMed ID: 32772302
[TBL] [Abstract][Full Text] [Related]
33. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Penzak SR; Rojas-Fernandez C
J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
[TBL] [Abstract][Full Text] [Related]
34. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
35. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
36. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
37. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
Zhang X; Jones DR; Hall SD
Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
Lee E; Shon JC; Liu KH
Biopharm Drug Dispos; 2016 Sep; 37(6):366-72. PubMed ID: 27323294
[TBL] [Abstract][Full Text] [Related]
39. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
